Hamster Polyomavirus Research: Past, Present and Future †

Burkhard Jandrig 1,*, Hans Krause 2, Wolfgang Zimmermann 3, Emilija Vasiliunaite 4, Alma Gedvilaite 4 and Rainer G. Ulrich 5,6

1 Department of Urology, University Medical Center Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
2 Charité—Universitätsmedizin Berlin, Urologische Klinik, Charitéplatz 1, 10117 Berlin, Germany; hans.krause@charite.de
3 LGC Genomics, BU Sequencing, Ostendstr. 25, 12459 Berlin, Germany; mzwimmermann77@alice-dsl.net
4 Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, LT-10257 Vilnius, Lithuania; emilija.vasiliunaite@gmc.vu.lt (E.V.); alma.gedvilaite@bti.vu.lt (A.G.)
5 Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Süderfer 10, 17493 Greifswald-Insel Riems, Germany; rainer.ulrich@fli.de
6 German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Insel Riems, 38124 Braunschweig, Germany
* Correspondence: burkhard.jandrig@med.ovgu.de
† Dedicated to Professor Siegfried Scherneck on the occasion of his 80th birthday.

Abstract: Hamster polyomavirus (Mesocricetus auratus polyomavirus 1, HaPyV) was discovered as one of the first rodent polyomaviruses at the end of the 1960s in a colony of Syrian hamsters (Mesocricetus auratus) affected by skin tumors. Natural HaPyV infections have been recorded in Syrian hamster colonies due to the occurrence of skin tumors and lymphomas. HaPyV infections of Syrian hamsters represent an important and pioneering tumor model. Experimental infections of Syrian hamsters of different colonies are still serving as model systems (e.g., mesothelioma). The observed phylogenetic relationship of HaPyV to murine polyomaviruses within the genus Alphapolyomavirus, and the exclusive detection of other cricetid polyomaviruses, i.e., common vole (Microtus arvalis polyomavirus 1) and bank vole (Myodes glareolus polyomavirus 1) polyomaviruses, in the genus Betapolyomavirus, must be considered with caution, as knowledge of rodent-associated polyomaviruses is still limited. The genome of HaPyV shows the typical organization of polyomaviruses with an early and a late transcriptional region. The early region encodes three tumor (T) antigens including a middle T antigen; the late region encodes three capsid proteins. The major capsid protein VP1 of HaPyV was established as a carrier for the generation of autologous, chimeric, and mosaic virus-like particles (VLPs) with a broad range of applications, e.g., for the production of epitope-specific antibodies. Autologous VLPs have been applied for entry and maturation studies of dendritic cells. The generation of chimeric and mosaic VLPs indicated the high flexibility of the VP1 carrier protein for the insertion of foreign sequences. The generation of pseudotype VLPs of original VP1 and VP2-foreign protein fusion can further enhance the applicability of this system. Future investigations should evaluate the evolutionary origin of HaPyV, monitor its occurrence in wildlife and Syrian hamster breeding, and prove its value for the generation of potential vaccine candidates and as a gene therapy vehicle.

Keywords: rodent polyomaviruses; virus discovery; Syrian hamster; genome organization; middle T antigen; tumor model; major capsid protein; virus-like particles

1. Introduction

Right from the start of developing the concepts of modern molecular biology and tumor biology, viruses such as the simian virus 40 (SV40; Macaca mulatta polyomavirus 1) and the murine polyomavirus (Mus musculus polyomavirus 1) have served as models...
for a fundamental understanding of eukaryotic gene regulation and gene expression as well as tumor induction and progression [1].

Polyomaviruses are nonenveloped circular double-stranded DNA viruses that infect a variety of vertebrate host species. In humans, mainly four polyomaviruses have been strongly associated with clinical disease. The Human polyomavirus 1 (HPyV-1; BK polyomavirus, BKPyV), Human polyomavirus 2 (HPyV-2, John Cunningham polyomavirus, JCPyV), Human polyomavirus 5 (Merkel cell polyomavirus, MCPyV), and Human polyomavirus 8 (Trichodysplasia spinulosa-associated polyomavirus, TSPyV) can cause severe diseases especially in immunosuppressed individuals. HPyV-1 is associated with nephropathy, a leading cause of kidney transplant failure, HPyV-2 can cause the demyelinating disease progressive multifocal leukoencephalopathy (PML), HPyV-5 is able to integrate into the cellular genome to cause a highly aggressive skin cancer (Merkel cell carcinoma), and HPyV-8 is an etiological factor for the dermatological disease Trichodysplasia spinulosa (TS). However, the mechanisms by which these viruses give rise to the relevant diseases are not well understood.

This review aims to describe the discovery and characterization of the hamster polyomavirus, its implication in the development of cancer, pathological features, and the application of its capsid-derived recombinant proteins for the generation of virus-like particles (VLPs). A timeline of objectives of hamster polyomavirus studies, leading researchers, and publication numbers are shown in Figure S1.

2. Hamster Polyomavirus—Its Discovery and Initial Characterization

Polyomaviruses have been identified in numerous mammalian species including members of different families of the order Rodentia [2]. Modern approaches such as generic polymerase chain reaction (PCR), rolling circle amplification, and high-throughput sequencing resulted in a rapid increase in the number of described rodent polyomaviruses, although not all of them are completely sequenced yet (see Table 1).

Table 1. Overview about rodent-associated polyomaviruses.

| Rodent Family | Subfamily | Polyomavirus Species                  | Polyomavirus Genus       | Reference |
|---------------|-----------|--------------------------------------|--------------------------|-----------|
| Muridae       | Murinae   | Mus musculus polyomavirus 1          | Alphapolyomavirus        | [3]       |
|               |           | Mus musculus polyomavirus 2          | Betapolyomavirus         | [4]       |
|               |           | Mus musculus polyomavirus 3          | Betapolyomavirus         | [5]       |
|               |           | Mus caroli polyomavirus 1 (high-throughput sequencing-based partial sequence information) | unclassified            | [6]       |
|               |           | Mus pahari polyomavirus 1            | unclassified             | [6]       |
|               |           | Apodemus flavicollis polyomavirus 1  | Alphapolyomavirus        | [2]       |
|               |           | Apodemus agrarius polyomavirus 1     | unclassified             | [6]       |
|               |           | Apodemus draco polyomavirus 1        | unclassified             | [6]       |
|               |           | Apodemus sylvaticus polyomavirus 1   | unclassified             | [6]       |
|               |           | Rattus norvegicus polyomavirus 1     | Alphapolyomavirus        | [7]       |
|               |           | Rattus norvegicus polyomavirus 2     | Betapolyomavirus         | [8]       |
|               |           | Rattus tanezumi polyomavirus 1       | unclassified             | [6]       |
| Family       | Subfamily | Genus             | Species           | Polyomavirus Type   | Reference |
|--------------|-----------|-------------------|-------------------|---------------------|-----------|
| Mastomys     |           | natalensis        | polyomavirus 1    | Betapolyomavirus    | [9]       |
| Mastomys     |           | natalensis        | polyomavirus 2    | Alphapolyomavirus   | [2]       |
| Mastomys     |           | natalensis        | polyomavirus 3    | Alphapolyomavirus   | [10]      |
| Niviventer   |           | confucianus       | polyomavirus 1    | unclassified        | [6]       |
|              |           |                   |                   |                     |           |
|              |           |                   |                   |                     |           |
| Gerbillinae  |           | Meriones          | uinguiculatus     | unclassified        | [6]       |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           |                   |                   |                     |           |
|              |           | Meriones          | meridianus        | unclassified        | [6]       |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           |                   |                   |                     |           |
| Gliridae     | Glirinae  | Glis              | glis              | Betapolyomavirus    | [2]       |
| Sciuridae    | Sciurinae | Sciurus            | carolinensis      | Betapolyomavirus    | [11]      |
|              |           |                   | variegatoides     | Alphapolyomavirus   | [11]      |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           |                   |                   |                     |           |
| Callosciurinae |         | Callosciurus      | prevostii         | Betapolyomavirus    | [11]      |
|              |           | erythraeus        | polyomavirus 1    | Alphapolyomavirus   | [11]      |
|              |           |                   |                   |                     |           |
| Cricetidae   | Arvicolina| Myodes            | glareolus         | Betapolyomavirus    | [12]      |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           | Microtus          | arvalis           | Betapolyomavirus    | [12]      |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           | Microtus          | fortes            | unclassified        | [6]       |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           | Eothenomys        | melanogaster      | unclassified        | [6]       |
|              |           |                   | polyomavirus 1    |                     |           |
| Sigmodontinae |         | Akodon            | montensis         | unclassified        | [14]      |
|              |           |                   | polyomavirus 1    |                     |           |
|              |           | Calomys           | tener             | unclassified        | [14]      |
|              |           |                   | polyomavirus 1    |                     |           |
| Echimyidae   | Echimyinae| Myocastor         | coypus            | Alphapolyomavirus   | [15]      |
|              |           |                   | polyomavirus 1    |                     |           |
| Dipodidae    | Dipodinae | Dipus             | sagitta           | unclassified        | [6]       |
|              |           |                   | polyomavirus 1    |                     |           |
(high-throughput sequencing-based partial sequence information)

| Genus     | Species                                | Host                | Date       |
|-----------|----------------------------------------|---------------------|------------|
| Allactaginae | Allactaga sibirica polyomavirus 1     | unknown             | [6]        |

However, the knowledge of rodent polyomaviruses is still very scarce. This is illustrated when comparing the number of known polyomaviruses in humans (n = 14) with those in more than 2000 rodent species (n = 34, see Table 1). Whereas three distinct polyomaviruses have been described in a very few rodent species, there is still only one complete virus genome known in hamsters.

A hamster polyomavirus (HaPyV; Mesocricetus auratus polyomavirus 1; previously Hamster papovavirus, HaPV) was first isolated from skin epitheliomas arising in the Syrian hamster colony in Berlin-Buch, Germany and described by Graffi et al. [13] (a screenshot of the paper is shown in Figure S2). The tumors appeared spontaneously in young animals of about 3 months to more than one year of age. Polyomavirus infections in hamsters were also reported from the United States (Newfield, NJ, [16]; Columbia, MO, [17]; New Haven, CT, [18]) and Europe (Bristol, GB, [19]; Salamanca, Spain, [20]). In general, HaPyV infections are rarely reported. Screening for polyomaviruses in laboratory hamsters is not officially required by the Federation of European Laboratory Animal Science Associations [21] and not rigorously demanded by local supervisory authorities.

Virus particles extracted from skin epithelioma caused lymphoma and leukemia when injected into newborn hamsters from a distinct and tumor-free colony bred in Potsdam, Germany [22]. The role of HaPyV as the causative agent of transmissible lymphoma was further investigated by Barthold et al. [23]. Lymphoma developed not only in the originally infected hamsters but also in hamsters maintained in direct and indirect contact. In addition, one of the contact hamsters developed cutaneous virus-containing epitheliomas. A hallmark of HaPyV is the capacity to infect both undifferentiated keratinocytes as well as lymphocytes and thereby to generate hair follicle and lymphoid tumors.

HaPyV particles were first detected on electron micrographs of primary skin sections [13]. The particles, about 40 nm in diameter, accumulated in large amounts in skin epithelioma. These are spherical particles with the typical icosahedral structure of polyomaviruses that are characterized by a molecular weight of $2.75 \times 10^6$, a sedimentation coefficient of 223 S, and a buoyant density of 1.340 g/mL [24]. The symmetry of the capsid was classified as T = 7 laevo [25]. Virus particles are assembled in the nuclei of keratinized cell layers and are abundant in the differentiated stratum corneum but absent in the proliferating cells of the stratum basale and stratum spinosum. In situ hybridization of whole body animal sections conducted before the appearance of epitheliomias demonstrated that thymus and spleen represent the most active virus reservoirs [26]. Accordingly, an accumulation of virus particles could be observed on electron micrographs of hamster thymus. In contrast to primary skin epitheliomas, virus particles could not be detected on electron micrographs of transplanted skin tumors. The absence of detectable viral genomes in total embryo tissues supports the model of horizontal transmission [17,19]. Although lymphomas induced by HaPyV were carefully examined for the presence of virus particles by electron microscopy, virus particles could not be found. Instead, different amounts (sometimes several thousands of copies) of extrachromosomal nonrandomly deleted free and/or integrated viral genomes accumulated in the tumors [20,26,27].
3. HaPyV Model Systems

The availability of experimental models is necessary in order to study the induction and growth processes of tumors and metastases. Experimental Syrian hamster models were created by the subcutaneous inoculation of virions isolated from skin tumors and HaPyV DNA purified from the virions [28]. Out of skin tumors, a spectrum of tumors was induced in a Syrian hamster colony, mainly lymphomas (>50%), but also sarcomas (8%) and mesotheliomas (2%) [29]. Mesothelioma became important because of its occurrence in humans after exposure to asbestos and also to non-asbestos-related noxa, e.g., mineral oils, metal dust, and opaque matter applications. Interestingly, the Syrian hamsters bearing primary mesotheliomas were female. This sex difference was maintained in transplantation experiments demonstrating an accelerated tumor growth in female as compared to male animals. The preference of female animals in mesothelioma induction and growth remains unclear.

Transgenic mice have been obtained by the microinjection of HaPyV supercoiled DNA into pronuclei of fertilized eggs of Gat:NMRI mice [30]. Analysis of different tissues in three generations showed the presence of the HaPyV transgene as extrachromosomal DNA and its expression preferentially in the thymus and the spleen. At the age of 18 months, four of seven founders developed skin papillomas histologically similar to that of the random-bred hamster tumors. In these epitheliomas, high amounts of episomal viral genomes were accumulated, whereas virus particles could not be detected. Two founder mice lines have developed lymphomas containing extrachromosomal viral genomes. Lymphomas and papillomas have been observed in 5- to 9-month-old F1 animals. F2 litters are affected by severe developmental and often lethal damage e.g., almost complete thymus depletion.

Transgenic mice in which the expression of the reporter gene lacZ is driven by the HaPyV early promoter have shown that this promoter displays a rather specific expression pattern restricted to hematopoietic organs, mainly thymus and spleen [31].

Reflection on former models could give important insights into carcinogenic processes and may open new therapeutic options.

4. HaPyV as Pathogen

HaPyV is transmitted horizontally via urine [32] or by biting and grooming behaviors. Infection is mainly associated with trichoepitheliomas (hair follicle tumors) and/or lymphoma or leukemia. In addition, the animals are suffering from subclinical effects, which mainly occur in older hamsters. There, the virus persists in the renal tubular epithelium. Trichoepitheliomas in hamsters have only been described in association with an HaPyV infection. HaPyV induces hair follicle keratinocyte proliferation, especially of the hair root epithelium. Alopecic nodules mainly develop on the head and spread to the neck, back, belly, and feet. Sometimes, multiple nodules converge to massive confluent layers [33]. Histologically, the tumors form cyst-like masses filled with cornified material, sometimes containing melanin. Virus particles are present especially in the cornified layer but are absent in the proliferating cells of the stratum basale and stratum spinosum. In some areas, scattered chronic inflammatory infiltrates of lymphocytes and macrophages could be observed [19].

Lymphomas are mainly associated with HaPyV infection of young virus-naïve hamsters. Mortality rates among these hamsters can reach 80% within 4 to 30 weeks following infection [17]. Affected sites are mesenteric lymph nodes and liver and with a lesser extent in kidneys, spleen, thymus, small intestine, or peripheral lymph nodes. Histologically, the neoplastic lymphocytes of B- or T-cell origin are large and immature. The invasion of adjacent tissue and metastasis occur often. The concurrent formation of skin tumors and lymphoma in a hamster individuum is a relatively rare event [18].

In an inbred colony of genetic audiogenic seizure Syrian golden hamsters (GASH:Sal) in Spain, a high incidence of non-Hodgkin, Burkitt-type-B-cell lymphoma was detected,
resulting in mortality within 1 to 2 weeks [20]. An indirect ELISA and Western blot analysis confirmed the presence of antibodies against the VP1 capsid protein of HaPyV in the sera not only from affected and non-affected GASH:Sal hamsters but also from control hamsters from the same breeding area.

So far, there are no treatment options for hamsters with HaPyV infection. Aggressive environmental decontamination of the virus has failed in some facilities [19]. As an increased use of personal protective equipment has also not been successful, culling is mainly recommended when the HaPyV infection is widespread within a colony.

5. Genome Characterization of HaPyV

With the emergence of recombinant technology in the mid-1970s [34,35], opportunities arose to obtain the DNA genome of HaPyV in a form that could be more easily managed, thus permitting extensive molecular characterization. Finally, around 1978 rules were established for physical and biological safety, including the distribution of safe bacterial host and plasmid vectors [36].

In the early 1980s, full-length HaPyV was inserted into BamHI-site of the bacterial plasmid pBR322 [37,38] permitting initial restriction enzyme mapping as well as electron microscopic analyses [39]. This initial cloning provided viral DNA for extended studies such as heteroduplex analysis, protein-binding site investigations, evolutionary sequence analysis, and transformation experiments [40–43].

The most comprehensive molecular characterization of the HaPyV genome including the deposition of the almost entire nucleotide sequence (5366 base pairs, bp, GenBank X02449, later corrected with modern sequencing techniques to 5372 bp, GenBank JX036360) as well as a comparison to other polyomavirus genomes was carried out during the mid-1980s at the Institute Gustave Roussy, Villejuif, France in collaboration with the group of Jean Feunteun [44,45].

With regard to viral gene expression, the early and late mRNA transcripts of HaPyV were detected on the basis of cDNA cloning and subsequent sequence determination [45] (Figure 1).

![Diagram of HaPyV Genome](image)

**Figure 1.** Genome organization of hamster polyomavirus. The double-stranded DNA genome of 5372 base pairs contains a noncoding control region (NCCR), an early transcriptional region
encoding three T antigens and a late transcriptional region encoding capsid proteins VP1, VP2, and VP3. The coding regions are depicted as shaded green, blue, light blue, and violet arrows. As for all polyomaviruses, the proximal N-terminal region of all three T antigens is identical. The VP2 represents an N-terminally prolonged VP3; i.e., the VP3 region is identical to the C-terminal part of VP2.

The synthesis of the early tumor (T) antigens and late viral proteins (VP) of HaPyV were confirmed indirectly by the heterologous synthesis of protein segments of large T (LT), middle T (MT), small T (ST), VP1, and VP2/VP3 in Escherichia coli and their reactivity with sera from naturally HaPyV-infected Syrian hamsters of the Z3 strain [46]. The viral major capsid protein VP1 was additionally confirmed by its reactivity with rabbit polyclonal antibodies raised against E. coli-expressed VP1 [25].

The genome characterization of HaPyV resulted in the identification of two putative in-frame translation initiation codons of VP1-open reading frame (ORF) encoding 384 and 388 amino acid (aa) residue-long VP1 variants [25]. The heterologous expression of both VP1-ORF variants in E. coli, yeast Saccharomyces cerevisiae, and insect cells resulted in the formation of VLPs [47–49]. In contrast, the sequencing of purified viral VP1 (GenBank AJ006015) suggested the second AUG codon as a translation initiation site or a post-translational N-terminal cleavage of VP1 [25]. As expected, the VP2 sequence (GenBank AJ006016) represents an N-terminally prolonged VP3 sequence (GenBank AJ006017).

Nucleotide sequences of HaPyV deposited in GenBank were compared using the multiple sequence alignment program MUSCLE embedded in CodonCode Aligner™. A phylogenetic tree built by the neighbor-joining method based on the matrix of pair-wise genetic distances between samples shows a closer relationship of the German isolate (Berlin) to the British (Bristol) or American (Columbia) sequences than to the Spanish (Salamanca) variants (see Figure 2). However, at the moment, very limited data are available in order to make statements about potential genetic relationships.

**Figure 2.** The nucleotide sequences of HaPyV strains from different Syrian hamster colonies available in GenBank were assembled and the contig formed with the phred-basecalling and the phrap-assembly tool available in the suite CodonCode Aligner v.9 (CodonCode Corp., Centerville, MA, USA). CodonCode Aligner also supported building neighbor-joining trees for the contig. The branch lengths of the neighbor-joining tree represent the distance between the samples. Part of the contig is shown on the right representing the area between nucleotides 3337 and 3404 of the Hamster polyomavirus isolate Berlin (GenBank JX036360). This area is located within the VP1 gene.

The initial molecular characterization of the genome already suggested a similarity of HaPyV to the murine polyomavirus (MuPyV; Mus musculus polyomavirus 1), both encoding a MT antigen, but a clear divergence to the primate polyomavirus SV40 and human polyomavirus HPyV-1 (BKPyV). The initial assumption of the exclusive occurrence of the MT antigen-encoding capacity in rodent polyomaviruses [50] must be withdrawn according to new data [2]: Some of the rodent-associated polyomaviruses, such as Mastomys natalensis polyomavirus 2, Rattus norvegicus polyomavirus 1, and Apodemus flavicollis polyomavirus 1 encode a MT, but Glis glis polyomavirus 1 does not. On the opposite side, two non-rodent-associated polyomaviruses also encode an MT antigen, i.e., Tupaia glis polyomavirus 1 and Philantomba monticola polyomavirus 1. Recent phylogenetic investigations of LT and VP1 amino acid sequences confirmed the previously documented close relationship of HaPyV to MuPyV [45] but also to other murine rodent associated polyomaviruses within the genus Alphapolyomavirus (Figure 3a,b).
Interestingly, other cricetid-associated polyomaviruses, i.e., bank vole (Myodes glareolus polyomavirus 1) and common vole (Microtus arvalis polyomavirus 1) polyomaviruses, belong to the genus Betapolyomavirus, distinct from the cricetid associated HaPyV. This current phylogenetic position of HaPyV must be considered with caution because it might be biased by the still limited knowledge of rodent-associated polyomaviruses.

6. Past, Present, and Future: HaPyV-Derived VLPs

VLPs can be produced by heterologous synthesis of viral capsid and/or envelope proteins and represent a very useful alternative to infectious virus particles with broad applications in basic and applied research [60]. The production of VLPs follows different approaches resulting in autologous, chimeric, mosaic, and pseudotype VLPs (Figure 4).
Autologous HaPyV-VP1 derived VLPs were used to compare their uptake mechanisms by human dendritic cells (DCs) to that of VLPs of other polyomaviruses [61]. These investigations profit also from the generation of VLPs harboring an enhanced green fluorescent protein (eGFP) insertion [62]. In addition, HaPyV-VP1 derived VLPs induce maturation of human DCs and a robust T-cell response [61]. E. coli-derived HaPyV VLPs were also shown to transfer foreign plasmid DNA into mammalian cells [49].

To exploit HaPyV VP1 as a carrier for foreign epitopes in VLPs, multiple epitope mapping studies were performed to identify potential insertion sites for foreign sequences. An initial evaluation of dihydrofolate reductase (DHFR) fusion proteins with different segments of HaPyV-VP1 resulted in the identification of the C-terminus of VP1 as an immunodominant and cross-reactive region that was not only detected by sera of infected tumor bearing Z3 and tumor-free PF hamsters but also by sera raised against SV40 and HPyV-2 (JCPyV) [48]. The C-terminal region of VP1 was confirmed as immunodominant and cross-reactive by the construction of bacteriophage fr fusion proteins [63]. In addition, the formation of phage fr-capsid protein derived chimeric VLPs confirmed the flexibility of the C-terminal region of HaPyV-VP1. A PepScan analysis identified linear epitopes within VP1 that showed different reactivities with sera from tumor-bearing and papilloma-free hamsters [48].

Sequence comparisons and prediction of the structure resulted in the identification of four flexible, variable, and surface-exposed regions within VP1 of HaPyV that represent, in addition to the C-terminal region, potential insertion sites for foreign epitopes [64]. Furthermore, various truncations or amino acid exchanges within the C-terminal region indicated the robustness of the VP1 assembly capacity but also potential limitations [65].

The insertion of a pentapeptide of the hepatitis B virus preS1 region allowed the formation of chimeric VLPs by VP1-preS epitope fusion proteins in S. cerevisiae [64] (Table 2, Figure 5b,d). The subsequent insertion of 45 and 120 amino acid-long N-terminal segments of Puumala orthohantavirus (PUUV) nucleocapsid (N) protein suggested a high insertion capacity of the VP1 carrier protein [66] (Table 2, Figure 5e,f).
Table 2. Overview about hamster polyomavirus-derived chimeric, mosaic and pseudotype virus-like particles.

| Chimeric/Mosaic/Pseudotype | Insertion Sites | GSSG Linker | Foreign Insert | Formation of Chimeric/Mosaic/Pseudotype VLPs | References |
|----------------------------|----------------|-------------|----------------|--------------------------------------------|------------|
| Chimeric                   |                |             |                |                                            |            |
| -L                         | preS1 (5 aa or 8 aa) | +          |                |                                            | [64,67]    |
| -L                         | MUC1 (9 aa)     | +          |                |                                            | [61]       |
| +L                         | MUC1 (9 aa)     | +          |                |                                            | [61]       |
| -L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| +L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| -L                         | PADRE (13 aa)   | +          |                |                                            | [67]       |
| -L                         | PUUV-N (45, 80 or 120 aa) | + |                |                                            | [66]       |
| -L                         | hTERT (9 or 15 aa) | +/-      |                |                                            | [69]       |
| -L                         | PUUV-Gc (99 aa) | +          |                |                                            | [70]       |
| -L                         | LCMV gp33 (9 aa) | +          |                |                                            | [71]       |
| -L                         | PrP (78 aa)     | +          |                |                                            |            |
| -L                         | PrP (37 aa)     | +          |                |                                            | [72]       |
| -L                         | PrP (92 aa)     | +          |                |                                            | [72]       |
| -L                         | PrP (46 aa)     | +          |                |                                            | [72]       |
| #1 (between aa positions 80 and 89) |             |             |                |                                            |            |
| -L                         | preS1 (5 aa) | +          |                |                                            | [64]       |
| -L                         | PUUV-N (45 or 120 aa) | - |                |                                            | [66]       |
| #2 (between aa positions 222 and 225) | -L | preS1 (5 aa) | +          |                                            | [64]       |
| #3 (between aa positions 243 and 247) | -L | preS1 (5 aa) | +          |                                            | [64]       |
| #4 (between aa positions 288 and 295) | -L | preS1 (5 aa) | +          |                                            | [64]       |
| +L                         | preS1 (8 aa)    | +          |                |                                            | [67]       |
| -L                         | MUC1 (9 aa)     | +          |                |                                            | [61]       |
| +L                         | MUC1 (9 aa)     | +          |                |                                            | [61]       |
| -L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| +L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| +L                         | PADRE (13 aa)   | +          |                |                                            | [67]       |
| -L                         | PUUV-N (45 or 120 aa) | + |                |                                            | [66]       |
|                       | eGFP (238 aa)  | +          |                |                                            | [73]       |
| #4 (between aa positions 288 and 295) | -L | TRP (9 aa) +MAGE (9 aa) | +/−   |                                            | [69]       |
|                         | HTERT (9 and 15 aa) | +/-   |                |                                            | [69]       |
|                         | PUUV-Gc (99 aa) | +          |                |                                            | [70]       |
|                         | LCMV gp33 (9 aa) | +          |                |                                            | [71]       |
| +L                         | PrP (78 aa)     | +/-       |                |                                            | [72]       |
| +L                         | PrP (37 aa)     | +/-       |                |                                            | [72]       |
| +L                         | PrP (92 aa)     | +          |                |                                            | [72]       |
| +L                         | PrP (46 aa)     | +          |                |                                            | [72]       |
| VP1 with one insert       |                |             |                |                                            |            |
| #1 (between aa positions 80 and 89) |             |             |                |                                            |            |
| +L                         | preS1 (5 aa)    | +          |                |                                            | [64]       |
| -L                         | MUC1 (9 aa)     | +          |                |                                            | [62]       |
| +L                         | MUC1 (9 aa)     | +          |                |                                            | [61]       |
| -L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| +L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| #1 (between aa positions 222 and 225) |             |             |                |                                            |            |
| +L                         | preS1 (5 aa)    | +          |                |                                            | [64]       |
| -L                         | PUUV-N (45 or 120 aa) | - |                |                                            | [66]       |
| #1 (between aa positions 243 and 247) |             |             |                |                                            |            |
| -L                         | puS (5 aa)      | +          |                |                                            | [64]       |
| +L                         | puS (8 aa)      | +          |                |                                            | [67]       |
| +L                         | MUC1 (9 aa)     | +          |                |                                            | [61]       |
| -L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| #1 (between aa positions 288 and 295) |             |             |                |                                            |            |
| +L                         | preS1 (5 aa)    | +          |                |                                            | [64]       |
| -L                         | puS (5 aa)      | +          |                |                                            | [64]       |
| +L                         | MUC1 (9 aa)     | +          |                |                                            | [62]       |
| -L                         | CEA (9 aa)      | +          |                |                                            | [68]       |
| #4 (between aa positions 288 and 295) | -L | TRP (9 aa) +MAGE (9 aa) | +/−   |                                            | [69]       |
|                         | HTERT (9 and 15 aa) | +/-   |                |                                            | [69]       |
|                         | PUUV-Gc (99 aa) | +          |                |                                            | [70]       |
|                         | LCMV gp33 (9 aa) | +          |                |                                            | [71]       |
| +L                         | PrP (78 aa)     | +/-       |                |                                            | [72]       |
| +L                         | PrP (37 aa)     | +/-       |                |                                            | [72]       |
| +L                         | PrP (92 aa)     | +          |                |                                            | [72]       |
| +L                         | PrP (46 aa)     | +          |                |                                            | [72]       |
| VP1 with two inserts       |                |             |                |                                            |            |
| #1 (between aa positions 80 and 89) |             |             |                |                                            |            |
| #1 (between aa positions 222 and 225) |             |             |                |                                            |            |
| #1 (between aa positions 243 and 247) |             |             |                |                                            |            |
| #1 (between aa positions 288 and 295) |             |             |                |                                            |            |
| #1 (between aa positions 288 and 295) |             |             |                |                                            |            |
| VP1 with three inserts | #1+#3+#4 | −L | TRP (9 aa), MAGE (9 aa), HTERT (9 aa) | + | [69] |
|------------------------|----------|----|--------------------------------------|---|-----|
| VP1 with four inserts  | #1+2+3+4 | +L | MUC1 (9 aa)                           | − | [61] |
|                        |          | +L | CEA (9 aa)                            | − | [68] |
| Mosaic                 |          |    |                                      |   |     |
| VP1+ VP1 with insert   | #4       | −L | eGFP (238 aa)                        | + | Gedvilaite, unpublished data |
| Pseudotype             |          |    |                                      |   |     |
| VP1 + VP2 fused with   |          |    |                                      |   |     |
| insert at its N terminus|          |    |                                      |   |     |

|                |          |    |                                      |   |     |
| VP1 + VP2 fused with insert at its N terminus |          |    |                                      |   |     |

+L, GSGG linker inserted; −L, no linker inserted; +, formation of VLPs; −, no formation of VLPs; +/−, mix of VLPs and pentamers; #1-4 different insertion sites between aa positions. **Abbreviations:** preS1, B-cell epitope of the surface protein of the hepatitis B virus; MUC1, CTL-epitope of human tumor-associated mucin 1; CEA, CTL-epitope of human tumor-associated carnoembryonic antigen; PADRE, universal T cell-specific epitope; PUUV-N; nucleocapsid protein of Puumala orthohantavirus (PUUV), strain Vranica-Hällnäs; HTERT, CTL-epitope of human telomerase reverse transcriptase; PUUV-Gc, C-terminal glycoprotein segment of PUUV strain Kazan; LCMV, lymphocytic choriomeningitis virus; PrP, mouse prion protein (used peptides: 78 aa long include aa 51–128; 37 aa long include aa 128–164; 92 aa long include aa 128–219; 46 aa long include aa 174–219 and 199 aa long include aa 23–231); TRP, CTL-epitope of human tyrosinase-related protein-2; MAGE, CTL-epitope of human MAGE A family protein; eGFP, enhanced green fluorescent protein; p16^INK4A^, human protein of high diagnostic relevance considered to be a potential marker for cells transformed by high-risk human papillomavirus; anti-VLY scFv-Fc, single chain variable fragment with human Fc IgG domain specific to bacterial cytolysin vaginolysin (VLY); anti-HBV scFv, single chain variable fragment specific to hepatitis B virus (HBV) surface antigen HBsAg; anti-HBV scFv-Fc, single chain variable fragment with human Fc IgG domain specific to HBV surface antigen HBsAg; GSSG, flexible glycine-serine-serine-glycine linker.
Figure 5. Electron-microscopical images of autologous VP1-derived virus-like particles (a), chimeric VP1-derived virus-like particles with hepatitis B virus preS1 peptide (b) or lymphocytic choriomeningitis virus gp30 peptide in insertion site #1 (c), HBV preS1 peptide, Puumala orthohantavirus nucleocapsid protein (N) amino acids 1–45 or 1–120 at insertion site #4 (d–f), mosaic virus-like particles with enhanced green fluorescent protein (eGFP) in site #4 (g) and pseudotype virus-like particles with a VP2 fusion of eGFP or single chain variable fragment with human Fc IgG domain (h,i), all produced in yeast Saccharomyces cerevisiae. The bar represents 100 nm.

The successful use of HaPyV-derived VLPs was continued by the insertion of various viral and non-viral epitopes and protein segments (see Table 2, Figure 5). The flexibility of this carrier system was enhanced by the insertion of flexible glycine–serine–serine–glycine (GSSG) linker sequences at the insertion sites [62,68]. Furthermore, HaPyV–VP1-derived chimeric VLPs demonstrated the potential to induce high insert-specific and long-lasting antibody responses, even without adjuvant co-application [62,68]. The strong immunogenicity was also evidenced by the generation of monoclonal antibodies to inserted Mucin 1 peptide (MUC1), PUUV N protein segment, and glycoprotein Gc segment [62]. Moreover, HaPyV VP1-derived chimeric VLPs were able to trigger the development of an effective insert-specific cytotoxic T-cell (CTL) response in vivo in mice when HaPyV-VP1 VLPs with inserted CTL epitope from surface glycoprotein of
Lymphocytic choriomeningitis virus (LCMV) GP33 were used for immunization [70]. In vitro human DCs primed with HaPyV-VP1 VLPs with inserted MUC1 peptide were able to stimulate autologous peripheral blood leukocytes [61].

The high insertion capacity of the carrier was also demonstrated by simultaneous insertions of short epitopes at multiple sites of VP1 [61,62,64,68,71] (Table 2). The insertion of short peptides of interest into VP1 protein is very useful for improvement of immunogenicity of these epitopes by providing high epitope densities. Nevertheless, despite some successful insertions of long peptides into VP1 protein [62,66], the insertion capacity for long foreign peptides is limited, as it apparently affects the correct folding and assembly of the chimeric VP1 protein. The assembly of VLPs could be recovered by generating mosaic VLPs consisting of VP1+insert fusion protein and non-modified VP1 (Gedvilaitė, unpublished data). The employment of VP1/VP2 pseudotype VLPs provides additional possibilities for protein engineering of the HaPyV carrier system, e.g., by increasing the insertion capacity. This approach allows the fusion of long polypeptides or protein complexes with VP2 protein, which assembles into pseudotype VLPs after co-expression with unmodified VP1 protein in the same yeast cell. HaPyV VP1/VP2-based pseudotype VLPs with inserted protein molecules displayed on the surface of VLPs were used as a carrier for different proteins such as p16\textsuperscript{INK4A} (156 aa), eGFP (238 aa), or even 473 aa long functionally active complex molecules such as single-chain antibody fragment fused with human antibody Fc fragment (scFv-Fc) [73,74] (Gedvilaitė, unpublished data; Figure 5). The recombinant scFv-Fc antibody molecules displayed on the surface of pseudotype VLPs were stable, correctly folded and functionally active in all used applications [74,75], and demonstrated the potential of recombinant VLPs as a highly efficient carrier for functionally active complex proteins. Pseudotype VLPs represent a new type of immunogen as they were able to induce a strong immune response against the target antigen p16\textsuperscript{INK4A} in immunized mice [73].

7. Conclusions

Currently, HaPyV represents the only well-characterized polyomavirus in cricetine rodents. A large-scale polyomavirus screening in wild Syrian hamsters and other hamster species is lacking. Therefore, the phylogenetic relationship of HaPyV to murine polyomaviruses within the genus Alphapolyomavirus and the exclusive detection of other cricetid polyomaviruses, i.e., common vole and bank vole polyomaviruses, in the genus Betapolyomavirus, must be considered with caution. The re-emergence of HaPyV outbreaks in Syrian hamster breeding and experimental units may suggest the necessity to continuously monitor breeding and hygiene regimens when implementing novel animals into existing breeding colonies. Further efforts are still needed to understand the different outcomes of HaPyV infections in Syrian hamsters of different origin, because no treatment options exist, and mainly all the hamsters in a colony have to be culled. HaPyV-VP1 and -VP1/VP2-derived VLPs represent a highly flexible carrier moiety for the insertion of foreign sequences of different size and origin offering a broad range of potential applications in basic and applied research. These virus-like particles are safe, easy to produce, and can be tailored for specific delivery or epitope presentation [77]. Future investigations should evaluate the evolutionary origin of HaPyV, monitor its occurrence in wildlife and Syrian hamster breeding, and prove its value for the generation of potential vaccine candidates and as a gene therapy vehicle.

Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/13/5/907/s1. Figure S1: Time chart of objectives of hamster polyomavirus studies, involved main persons and number of publications when searching PubMed, Figure S2: Screenshot of the title of the first paper describing a hamster polyomavirus, typical multiple skin tumors and a picture by electron microscopy [13], Table S1: Methods and sequences used for phylogenetic analyses to get phylogenetic relationships of polyomaviruses based on LTag/VP1 amino acid sequences.
Author Contributions: Conceptualization, B.J. and R.G.U.; Visualization, E.V. and A.G.; Writing—Original draft preparation, B.J.; A.G.; H.K.; W.Z. and R.G.U.; Writing—Review and Editing, B.J.; H.K.; W.Z.; E.V.; A.G. and R.G.U. All authors have read and agreed to the published version of the manuscript.

Funding: The work in the laboratory of R.G.U. was financially supported by the German Center of Infection Research (DZIF, TTU “Emerging Infections”).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: B.J.: H.K.; W.Z. and R.G.U. want to thank their academic supervisor and friend Siegfried Schernbeck for his encouragement during their graduate studies, supervision of their research work, and long-lasting support even after their scientific critical reading diverted. The critical reading and comments of Constanze Zeller are kindly acknowledged.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. DeCaprio, J.A.; Imperiale, M.J.; Major, E.O. Polyomaviruses. In Fields Virology, 6th ed.; Knipe, D.M., Howley, P.W., Eds.; Wolters Kluwer: Alphen aan den Rijn, The Netherlands, 2013; pp. 1633–1661.
2. Ehlers, B.; Anoh, A.E.; Ben Salem, N.; Broll, S.; Couacy-Hymann, E.; Fischer, D.; Gedvilaite, A.; Ingenhutt, N.; Liebmann, S.; Martin, M.; et al. Novel Polyomaviruses in Mammals from Multiple Orders and Reassessment of Polyomavirus Evolution and Taxonomy. Viruses 2019, 11, 930, doi:10.3390/v11090930.
3. Gross, L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc. Soc. Exp. Biol. Med. 1953, 83, 414–421.
4. Kilham, L.; Murphy, H.W. A pneumotropic virus isolated from C3H mice carrying the Bittner Milk Agent. Proc. Soc. Exp. Biol. Med. 1953, 82, 133–137.
5. Williams, S.H.; Che, X.; Garcia, J.A.; Klena, J.D.; Lee, B.; Muller, D.; Ulrich, W.; Corrigan, R.M.; Nichol, S.; Jain, K.; et al. Viral Diversity of House Mice in New York City. MBio 2018, 9, doi:10.1128/mBio.01354-17.
6. Wu, Z.; Lu, L.; Du, J.; Yang, L.; Ren, X.; Liu, B.; Jiang, J.; Yang, J.; Dong, J.; Sun, L.; et al. Comparative analysis of rodent and small mammal viromes to better understand the wildlife origin of emerging infectious diseases. Microbiome 2018, 6, 178, doi:10.1186/s40168-018-0554-9.
7. Ehlers, B.; Richter, D.; Matuschka, F.R.; Ulrich, R.G. Genome Sequences of a Rat Polyomavirus Related to Murine Polyomavirus, Rattus norvegicus Polyomavirus 1. Genome Announce. 2015, 3, doi:10.1128/genomeA.00997-15.
8. Rigatti, L.H.; Topton, T.; Newsome, J.T.; Moore, P.S.; Chang, Y. Identification and Characterization of Novel Rat Polyomavirus 2 in a Colony of X-SCID Rats by P-PIT assay. mSphere 2016, 1, doi:10.1128/mSphere.00334-16.
9. Orba, Y.; Kobayashi, S.; Nakamura, I.; Ishii, A.; Hang’ombe, B.M.; Mweene, A.S.; Thomas, Y.; Kimura, T.; Sawah, H. Detection and characterization of a novel polyomavirus in wild rodents. J. Gen. Virol. 2011, 92 Pt 4, 789–795.
10. Calvignac-Spencer, S.; Kouadio, L.; Couacy-Hymann, E.; Sogoba, N.; Rosenke, K.; Davison, A.J.; Leendertz, F.; Jarvis, M.A.; Feldmann, H.; Ehlers, B. Multiple DNA viruses identified in multimammate mouse (Mastomys natalensis) populations from across regions of sub-Saharan Africa. Arch. Virol. 2020, 165, 2291–2299.
11. Schulze, V.; Lurz, P.W.W.; Ferrari, N.; Romeo, C.; Steele, M.A.; Marino, S.; Mazzamuto, M.V.; Calvignac-Spencer, S.; Schlottau, K.; Beer, M.; et al. Search for polyoma-, herpes-, and bornaviruses in squirrels of the family Sciuridae. Virol J. 2020, 17, 1–21.
12. Nainys, J.; Timinskas, A.; Schneider, J.; Ulrich, R.G.; Gedvilaite, A. Identification of Two Novel Members of the Tentative Genus Wukipolyomavirus in Wild Rodents. PLoS ONE 2015, 10, e0140916.
13. Graffi, A.; Schramm, T.; Bender, E.; Bierwolf, D.; Graffi, I. On a new virus containing skin tumor in golden hamster. Arch. Gesamtwirtschftsforsh. 1967, 30, 277–283. (In German)
14. Maia, F.G.M.; de Souza, W.M.; Sabino-Santos, G., Jr.; Fumagalli, M.J.; Modha, S.; Murcia, P.R.; Figueiredo, L.T.M. A novel polyomavirus in sigmodontine rodents from Sao Paulo State, Brazil. Arch. Virol. 2018, 163, 2913–2915.
15. da Silva, M.S.; Cibulski, S.P.; Alves, C.; Weber, M.N.; Budaszewski, R.F.; Silveira, S.; Mosena, A.C.S.; Mayer, F.Q.; Goltz, L.V.; Campos, R.; et al. New polyomavirus species identified in nutria, Myocastor coypus polyomavirus 1. Arch. Virol. 2018, 163, 3203–3206.
16. Coggins, J.H. Jr.; Bellomy, B.B.; Thomas, K.V.; Pollock, W.J. B-cell and T-cell lymphomas and other associated diseases induced by an infectious DNA viroid-like agent in hamsters (Mesocricetus auratus). Am. J. Pathol. 1983, 110, 254–266.
17. Simmons, J.H.; Riley, L.K.; Franklin, C.L.; Besch-Williford, C.L. Hamster polyomavirus infection in a pet Syrian hamster (Mesocricetus auratus). Vet. Pathol. 2001, 38, 441–446.
18. Beck, A.P.; Compton, S.R.; Zeiss, C.J. Pathology in practice. HaPyV infection in a pet Syrian hamster. J. Am. Vet. Med. Assoc. 2014, 244, 1037–1039.

19. Foster, A.P.; Brown, P.J.; Jandrig, B.; Grosch, A.; Voronkova, T.; Scherneck, S.; Ulrich, R. Polyomavirus infection in hamsters and trichoepitheliomas/cutaneous adnexal tumours. Vet. Rec. 2002, 151, 13–17.

20. Munoz, L.J.; Ludena, D.; Gedvilaité, A.; Zvirbliene, A.; Jandrig, B.; Voronkova, T.; Ulrich, R.G.; Lopez, D.E. Lymphoma outbreak in a GASH-Sal hamster colony. Arch. Virol. 2013, 158, 2255–2265.

21. Mähler, C.M.; Berard, M.; Feinstein, R.; Gallagher, A.; Illgen-Wilcke, B.; Pritchett-Corning, K.; Raspa, M. FELASA working group on revision of guidelines for health monitoring of rodents and rabbits. FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Lab. Anim. 2014, 48, 178–192.

22. Graff, A.; Bender, E.; Schramm, T.; Kuhn, W.; Schneider, F. Induction of transmissible lymphomas in Syrian hamsters by application of DNA from viral hamster papovavirus-induced tumors and by cell-free filtrates from human tumors. Proc. Natl. Acad. Sci. USA 1969, 64, 1172–1175.

23. Barthold, S.W.; Bhatt, P.N.; Johnson, E.A. Further evidence for papovavirus as the probable etiology of transmissible lymphoma of Syrian hamsters. Lab. Anim. Sci. 1987, 37, 283–288.

24. Böttger, M.; Scherneck, S. Heterogeneity, molecular weight and stability of an oncogenic papovavirus of the Syrian hamster. Arch. Geschwulstforsch. 1985, 55, 225–233.

25. Siray, H.; Ozel, M.; Jandrig, B.; Voronkova, T.; Jia, W.; Zocher, R.; Arnold, W.; Scherneck, S.; Kruger, D.H.; Ulrich, R. Capsid protein-encoding genes of hamster polyomavirus and properties of the viral capsid. Virus Genes 1999, 18, 39–47.

26. Prokopf, H.; Jandrig, B.; Arnold, W.; Scherneck, S. Generation of lymphoma-type variant hamster polyomavirus genomes in hamsters susceptible to lymphoma induction. Arch. Virol. 1997, 142, 53–63.

27. Scherneck, S.; Delmas, V.; Vogel, F.; Feunteun, J. Induction of lymphomas by the hamster papovavirus correlates with massive replication of nonrandomly deleted extrachromosomal viral genomes. J. Virol. 1987, 61, 3992–3998.

28. Arnold, W.; Scherneck, S. Syrian hamster mesothelioma models: Detection of hamster polyomavirus DNA in ascitic and solidly growing tumors. Arch. Geschwulstforsch. 1990, 60, 435–437.

29. Mehnert, W.H.; Bender, E.; Graff, A.; Schramm, T.; Wildner, G.P. Mesotheliomas in golden hamster. IV. Further studies on the macroscopy and histology including a literature survey. Arch. Geschwulstforsch. 1974, 43, 22–35. (In German)

30. Hoffmann, S.; Scherneck, S.; Becker, K.; Arnold, W. Hamster papovavirus induces papillomas and lymphomas in transgenic mice. Biol. Zentralbl. 1989, 108, 13–19.

31. Hauff, P.; Thomschke, A.; Basikow, H.-G.; Hoffmann, S. Histological investigation of lymphomas, leukaemias and skin tumors in hamsters and HaPyV-transgenic mice. Med. Vet. 1992, 9, 91–92.

32. Scherneck, S.; Feunteun, J. The hamster papovavirus—a brief review of recent knowledge. Arch. Geschwulstforsch. 1990, 60, 271–278.

33. Graff, A.; Schramm, T.; Graff, I.; Bierwolf, D.; Bender, E. Virus-associated skin tumors of the Syrian hamster: Preliminary note. J. Natl. Cancer Inst. 1968, 40, 867–873.

34. Cohen, S.N.; Chang, A.C.; Boyer, H.W.; Helling, R.B. Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. USA 1973, 70, 3240–3244.

35. Jackson, D.A.; Symons, R.H.; Berg, P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA 1972, 69, 2904–2909.

36. Berg, P.; Baltimore, D.; Boyer, H.W.; Cohen, S.N.; Davis, R.W.; Hogness, D.S.; Nathans, D.; Roblin, R.; Watson, J.D.; Weissman, S.; et al. Potential biohazards of recombinant DNA molecules. Science 1974, 185, 303.

37. Sutcliffe, J.G. pBR322 restriction map derived from the DNA sequence: Accurate DNA size markers up to 4361 nucleotide pairs long. Nucleic Acids Res. 1978, 5, 2721–2728.

38. Vogel, F.; Zimmermann, W.; Krause, H.; Scherneck, S. Characterization of the DNA of the hamster papovavirus: I. Genom length and molecular cloning. Arch. Geschwulstforsch. 1984, 54, 433–441.

39. Zimmermann, W.; Krause, H.; Scherneck, S.; Feunteun, J.; Geissler, E. Molecular cloning of the hamster papovavirus genome in Escherichia coli plasmid vector pBR322. Gene 1984, 29, 243–246.

40. Scherneck, S.; Vogel, F.; Nguyen, H.L.; Feunteun, J. Sequence homology between polyoma virus, simian virus 40, and a papilloma-producing virus from a Syrian hamster: Evidences for highly conserved sequences. Virology 1984, 137, 41–48.

41. Vogel, F.; Rhode, K.; Scherneck, S.; Bastien, C.; Delmas, V.; Feunteun, J. The hamster papovavirus: Evolutionary relationships with other polyomaviruses. Virology 1986, 154, 335–343.

42. Vogel, F.; Scherneck, S. Characterization of the DNA of the hamster papovavirus: IV. Transcription mapping of cal-thymus DNA polymerase II. Arch. Geschwulstforsch. 1986, 56, 81–87.

43. Vogel, F.; Scherneck, S.; Rohde, K. Characterization of the DNA of the hamster papovavirus. III. Mapping of inverted repeated DNA sequences within the viral genome. Biomed. Biochim. Acta 1986, 45, 887–895.

44. Bastien, C.; Delmas, V.; Scherneck, S.; Feunteun, J. Restriction endonuclease cleavage map of the DNA of hamster papovavirus. Biomed. Biochim. Acta 1985, 44, K43–50.

45. Delmas, V.; Bastien, C.; Scherneck, S.; Feunteun, J. A new member of the polyomavirus family: The hamster papovavirus. Complete nucleotide sequence and transformation properties. EMBO J. 1985, 4, 1279–1286.
46. Ulrich, R.; Sommerfeld, K.; Schroder, A.; Prokopf, H.; Arnold, W.; Kruger, D.H.; Scherneck, S. Hamster polyomavirus-encoded proteins: Gene cloning, heterologous expression and immunoreactivity. *Virus Genes* **1996**, *12*, 265–274.

47. Sasnauskas, K.; Buzaitė, O.; Vogel, F.; Jandrig, B.; Razanskas, R.; Staniulis, J.; Scherneck, S.; Kruger, D.H.; Ulrich, R. Yeast cells allow high-level expression and formation of polyomavirus-like particles. *Biol. Chem.* **1999**, *380*, 381–386.

48. Siray, H.; Frommel, C.; Voronkova, T.; Hahn, S.; Arnold, W.; Schneider-Mergener, J.; Scherneck, S.; Ulrich, R. An immunodominant, cross-reactive B-cell epitope region is located at the C-terminal part of the hamster polyomavirus major capsid protein VP1. *Viral Immunol.* **2000**, *13*, 533–545.

49. Voronkova, T.; Kazaks, A.; Ose, V.; Ozel, M.; Scherneck, S.; Pumpens, P.; Ulrich, R. Hamster polyomavirus-derived virus-like particles are able to transfer in vitro encapsidated plasmid DNA to mammalian cells. *Virus Genes* **2007**, *34*, 303–314.

50. Soeda, E.; Maruyama, T.; Arrand, J.R.; Griffin, B.E. Host-dependent evolution of three papova viruses. *Nature* **1980**, *285*, 165–167.

51. Li, W.; Godzik, A. Cd-hit: A fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics* **2006**, *22*, 1658–1659.

52. Katoh, K.; Misawa, K.; Kuma, K.; Miyata, T. MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* **2002**, *30*, 3059–3066.

53. Rose, R.; Golosova, O.; Sukhomlinov, D.; Tiusnov, A.; Prosperi, M. Flexible design of multiple metagenomics classification pipelines with UGENE. *Bioinformatics* **2019**, *35*, 1963–1965.

54. Castresana, J. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. *Mol. Biol. Evol.* **2000**, *17*, 540–552.

55. Dereeper, A.; Guignon, V.; Blanc, G.; Audic, S.; Buffet, S.; Chevenet, F.; Dufayard, J.F.; Guindon, S.; Lefort, V.; Lescot, M.; et al. Phylogeny.fr: Robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.* **2008**, *36*, doi:10.1093/nar/gkn180.

56. Miller, M.A.; Pfeiffer, W.; Schwartz, T. Creating the CIPRES Science Gateway for Inference of Large Phylogenetic Trees. In *Proceedings of the Gateway Computing Environments Workshop (GCE)*, New Orleans, LA, USA, 14 November 2010; pp. 1–8.

57. Kozlov, A.M.; Darriba, D.; Flouri, T.; Morel, B.; Stamatakis, A. RAxML-NG: A fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. *Bioinformatics* **2019**, *35*, 4453–4455.

58. Lemoine, F.; Domelevo Entfellner, J.B.; Wilkinson, E.; Correia, D.; Dávila Felipe, M.; De Oliveira, T.; Gascuel, O. Renewing Felsenstein's phylogenetic bootstrap in the era of big data. *Nature* **2018**, *556*, 452–456.

59. Letunic, I.; Bork, P. Interactive Tree Of Life (iTOl) v4: Recent updates and new developments. *Nucleic Acids Res.* **2019**, *47*, W256–W259.

60. Diederich, S.; Gedvilaite, A.; Zvirbliene, A.; Kazaks, A.; Sasnauskas, K.; Johnson, N.; Ulrich, R. Virus-like particles: A versatile tool for basic and applied research on emerging and reemerging viruses. In *Viral Nanotechnology*, Khudyakov, Y., Pumpens, P., Eds.; CRC Press: Boca Raton, FL, USA, 2015.

61. Dorn, D.C.; Lawatscheck, R.; Zvirbliene, A.; Aleksaite, E.; Pecher, G.; Sasnauskas, K.; Ozel, M.; Raftery, M.; Schönrich, G.; Ulrich, R.G.; et al. Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytototoxic T-cell epitope. *Viral Immunol.* **2008**, *21*, 12–27.

62. Zvirbliene, A.; Samonskyte, L.; Gedvilaite, A.; Voronkova, T.; Ulrich, R.; Sasnauskas, K. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles. *J. Immunol. Methods* **2006**, *311*, 57–70.

63. Voronkova, T.; Grosch, A.; Kazaks, A.; Ose, V.; Skrastina, D.; Sasnauskas, K.; Jandrig, B.; Arnold, W.; Scherneck, S.; Pumpens, P.; et al. Chimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice. *Viral Immunol.* **2002**, *15*, 627–643.

64. Gedvilaite, A.; Frommel, C.; Sasnauskas, K.; Micheel, B.; Ozel, M.; Behrsing, O.; Staniulis, J.; Jandrig, B.; Scherneck, S.; Ulrich, R. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. *Virology* **2000**, *273*, 21–35.

65. Gedvilaite, A.; Dorn, D.C.; Sasnauskas, K.; Pecher, G.; Bulavaite, A.; Lawatscheck, R.; Staniulis, J.; Dalianis, T.; Ramqvist, T.; Schönrich, G.; et al. Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. *Virology* **2006**, *354*, 252–260.

66. Gedvilaite, A.; Zvirbliene, A.; Staniulis, J.; Sasnauskas, K.; Kruger, D.H.; Ulrich, R. Segments of Psuama hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice. *Virology* **2004**, *313*, 51–68.

67. Gedvilaite, A.; Kucinskaite-Kodzė, I.; Lasickiene, R.; Timinskas, A.; Vaitiekaitė, A.; Ziogienė, D.; Zvirbliene, A. Evaluation of Trichodysplasia spinulosa-associated polyomavirus capsid protein as a new carrier for construction of chimeric virus-like particles harboring foreign epitopes. *Viruses* **2015**, *7*, 4204–4229.

68. Lawatscheck, R.; Aleksaite, E.; Schenk, J.A.; Micheel, B.; Jandrig, B.; Holland, G.; Sasnauskas, K.; Gedvilaite, A.; Ulrich, R.G. Chimeric polyomavirus-derived virus-like particles: The immunogenicity of an inserted peptide applied without adjuvant to mice depends on its insertion site and its flanking linker sequence. *Viral Immunol.* **2007**, *20*, 453–460.

69. Aleksaite, E.; Gedvilaite, A. Generation of chimeric hamster polyomavirus VP1 virus-like particles harboring three tumor-associated antigens. *Biologia* **2006**, *3*, 83–87.

70. Zvirbliene, A.; Kucinskaite-Kodzė, I.; Razanskiene, A.; Petraityte-Buneikiene, R.; Klemba, B.; Ulrich, R.G.; Gedvilaite, A. The use of chimeric virus-like particles harbouring a segment of hantavirus Gc glycoprotein to generate a broadly-reactive hantavirus-specific monoclonal antibody. *Viruses* **2014**, *6*, 640–660.
71. Mazeike, E.; Gedvilaitė, A.; Blohm, U. Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope. *Virus Res.* 2012, 163, 2–10.

72. Eiden, M.; Gedvilaitė, A.; Leidel, F.; Ulrich, R.G.; Groschup, M.H. Vaccination with prion peptide-displaying polyomavirus-like particles prolongs incubation time in scrapie-infected mice. *Viruses* 2021, 3, 811.

73. Gedvilaitė, A.; Aleksaite, E.; Staniulis, J.; Ulrich, R.; Sasnauskas, K. Size and position of truncations in the carboxy-terminal region of major capsid protein VP1 of hamster polyomavirus expressed in yeast determine its assembly capacity. *Arch. Virol.* 2006, 151, 1811–1825.

74. Lasickiene, R.; Gedvilaitė, A.; Norkiene, M.; Simanaviciene, V.; Sezaite, I.; Dekaminaviciute, D.; Shikova, E.; Zvirbliene, A. The use of recombinant pseudotype virus-like particles harbouring inserted target antigen to generate antibodies against cellular marker p16INK4A. *Sci. World J.* 2012, 2012, 8, doi:10.1100/2012/263737.

75. Plekaityte, M.; Zvirbliene, A.; Sezaite, I.; Gedvilaitė, A. Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin. *Microb. Cell Fact.* 2011, 10, 1–13.

76. Plekaityte, M.; Bremer, C.M.; Gedvilaitė, A.; Kucinskaite-Kodze, I.; Glebe, D.; Zvirbliene, A. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen. *BMC Biotechnol.* 2015, 15, 85, doi:10.1186/s12896-015-0203-3.

77. Teunissen, E.A.; de Raad, M.; Mastrobattista, E. Production and biomedical applications of virus-like particles derived from polyomaviruses. *J. Control. Release* 2013, 172, 305–321.